Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE2016 in EGFR-expressing solid tumors
NCT06415487Phase 1Recruiting
- Sponsor
- Acepodia
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Native Immune Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of ACE2016 in solid tumor (3 arms), sponsored by Acepodia. Primary endpoints: Incidence of Dose-Limiting Toxicities at 1 year, Incidence of AESIs, Grade 3+ TEAEs, SAEs at 1 year and 3 more. Started Aug 2024; status: recruiting.
02
Drugs
ACE2016
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06415487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415487.